PMID- 35119622
OWN - NLM
STAT- MEDLINE
DCOM- 20220411
LR  - 20221207
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
VI  - 39
IP  - 4
DP  - 2022 Apr
TI  - Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly 
      Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study.
PG  - 1582-1595
LID - 10.1007/s12325-022-02053-0 [doi]
AB  - INTRODUCTION: The method of therapy administration and injection device 
      characteristics have been documented to influence perceptions and preference of 
      treatment among patients with type 2 diabetes (T2D). We aimed to assess the 
      metabolic effectiveness and patient-reported satisfaction of once-weekly 
      semaglutide compared to liraglutide in suboptimally controlled patients with T2D. 
      METHODS: We conducted this single-center cohort study at diabetes center clinics 
      at a tertiary care hospital between February 2021 and August 2021. We included 
      suboptimally controlled patients with T2D who had been treated with liraglutide 
      for at least 3 months at baseline, then shifted to once-weekly semaglutide and 
      followed up for the same period. Ambulatory glucose profile (AGP) metrics [i.e., 
      mean glucose level, glycemic variability (GV), time above range (TAR), and time 
      in range (TIR)] for baseline and follow-up were compared. To assess the 
      satisfaction with shifting, we used the valid Arabic version of the Diabetes 
      Treatment Satisfaction Questionnaire status (DTSQs) and change (DTSQc) while the 
      injection device preference was assessed using the Diabetes Injection Device 
      Preference Questionnaire (DID-PQ). RESULTS: We included 52 patients (25 male and 
      27 female), with a mean age of 48 (+/- 6) years and a mean diabetes mellitus 
      duration of 7.27 (+/- 3.79) years. We observed a significantly decreased mean HbA1c 
      level following semaglutide treatment (7.79% at study end vs. 8.07% at baseline, 
      p < 0.001) and body weight (84.64 +/- 7.68 vs. 87.15 +/- 8.011, p < 0.001). Compared 
      to the glucometrics data at baseline, we observed a significantly improved mean 
      average glucose, GV, TAR, and TIR (p < 0.001). Data from the DTSQs and DTSQc 
      questionnaires showed a high level of patient-reported satisfaction after 
      shifting to semaglutide treatment. All patients preferred/strongly preferred 
      once-weekly semaglutide over liraglutide in most DID-PQ questionnaire domains. 
      CONCLUSIONS: Switching from once-daily liraglutide to once-weekly semaglutide led 
      to improvements in both clinical measures of glycemic control and 
      patient-reported satisfaction.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Healthcare Ltd., part 
      of Springer Nature.
FAU - Al Hayek, Ayman A
AU  - Al Hayek AA
AUID- ORCID: 0000-0002-3483-3196
AD  - Department of Endocrinology and Diabetes, Diabetes Treatment Center, Prince 
      Sultan Military Medical City, P.O. Box 7897, Riyadh, 11159, Saudi Arabia. 
      ayman.alhayek@yahoo.com.
FAU - Al Dawish, Mohamed A
AU  - Al Dawish MA
AD  - Department of Endocrinology and Diabetes, Diabetes Treatment Center, Prince 
      Sultan Military Medical City, P.O. Box 7897, Riyadh, 11159, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20220204
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 53AXN4NNHX (semaglutide)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 839I73S42A (Liraglutide)
MH  - Blood Glucose
MH  - Cohort Studies
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Female
MH  - Glucagon-Like Peptides/therapeutic use
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents
MH  - Liraglutide/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Patient Reported Outcome Measures
MH  - Patient Satisfaction
MH  - Personal Satisfaction
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Glucagon-like peptide 1 receptor agonist
OT  - Liraglutide
OT  - Semaglutide
OT  - Treatment satisfaction
OT  - Type 2 diabetes mellitus
EDAT- 2022/02/05 06:00
MHDA- 2022/04/12 06:00
CRDT- 2022/02/04 12:13
PHST- 2021/12/14 00:00 [received]
PHST- 2022/01/17 00:00 [accepted]
PHST- 2022/02/05 06:00 [pubmed]
PHST- 2022/04/12 06:00 [medline]
PHST- 2022/02/04 12:13 [entrez]
AID - 10.1007/s12325-022-02053-0 [pii]
AID - 10.1007/s12325-022-02053-0 [doi]
PST - ppublish
SO  - Adv Ther. 2022 Apr;39(4):1582-1595. doi: 10.1007/s12325-022-02053-0. Epub 2022 
      Feb 4.